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Abstract
Mycobacteria are the unique group of bacteria that are currently used in antitumoral 
immunotherapy. Specifically, intravesical instillation of viable cells of Mycobacterium 
bovis Bacillus Calmette-Guérin (BCG), after transurethral resection of non-muscle 
invasive bladder cancer, is the most efficacious treatment for avoiding recurrence and 
progression of the disease. BCG has been used for the last 35 years for bladder cancer 
treatment, but other mycobacteria or mycobacteria components are currently under pre-
clinical and clinical studies for the immunotherapeutic treatment of non-invasive bladder 
cancer and also of other types of tumors located at the urinary system. Those are, for 
instance, cell wall extracts or heat-killed forms from BCG or other mycobacteria such 
as Mycobacterium phlei or Mycobacterium indicus pranii (MIP) or even viable cells from 
non-pathogenic mycobacteria such us Mycobacterium brumae. A review of the literature 
in which mycobacteria components, non-viable mycobacteria, and viable mycobacteria 
have been used for these different cancers will be performed. In this chapter, the func-
tion of mycobacteria as antitumor agents will be then analyzed, awarding the audience a 
broad knowledge of one of the beneficial applications of mycobacteria, which are usually 
introduced as dangerous microorganisms.
Keywords: BCG, bladder cancer, immunotherapy, Mycobacterium brumae, Mycobacterium 
phlei
1. Introduction
Since Science journal chose cancer immunotherapy as the breakthrough of the year in 2013, 
with only a few evidence of its efficacy and consequences, this field is now in fashion [1]. 
Immunotherapies follow extremely diverse strategies, and the only point they have in com-
mon is that all of them activate somehow the cancer patient’s immune system to attack tumor 
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cells. In fact, tumor cells are supposed to be recognized by the immune system as foreign, 
however, in the cases in which cancer progresses because the tumor and the immune sys-
tem reach equilibrium that drives to immunotolerance. Immunotherapies include antibodies 
against tumor epitopes, cytokines, checkpoint inhibitors that break the equilibrium, oncolytic 
virus, T cell therapy using T cells removed from the patient and modified with chimeric anti-
gen receptors (CARs), and finally, therapeutic vaccines and adjuvants which are the most 
ancient immunotherapies that exist.
1.1. Prechemotherapeutic era: the first association between mycobacteria and cancer
The first thoughts about a possible intervention of the immune system in the clearance of 
tumors were made at the beginning of the nineteenth century (Figure 1). It was observed 
that in cancer patients who underwent a gas gangrene, caused by Clostridium, their tumors 
regressed [2]. Later three different physicians independently made the same observations: 
first Busch in 1868, then Fehleisen in 1882, and, finally, Coley in 1891 observed tumor shrink-
age in patients suffering from erysipelas. From their observations, all three had the same idea: 
exposing their cancer patients to the infectious agent. At that time, Busch ignored that ery-
sipelas was an infectious disease caused by Streptococcus pyogenes (Fehleisen would describe 
this later [3]) which resulted in the death of his first patient due to the infection despite the 
Figure 1. Time course of the development of BCG immunotherapy and studies using mycobacteria-derived agents 
carried out for BC treatment. 1Alone or in combination with chemotherapy. 2In combination with chemotherapy and 
radiotherapy.
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regression of the tumor. Coley was the first one who systematically exposed their patients to 
infectious agents; he treated more than 1000 patients. The combination of the bacterial prod-
ucts of S. pyogenes and Serratia marcescens became the well-known Coley’s toxins [3]. Although 
the efficacy of Coley’s toxins became later controversial, nowadays it is correctly considered 
based on an immunotherapeutic effect [4]. Another relevant scientist who extensively con-
tributed to cancer understanding and cure through immunotherapy was Clowes, who sys-
tematized the methodology to monitor tumor size in transplantable animal cancer models. 
He dedicated part of his life in seeking the immunomodulating agent responsible for tumor 
clearance [5]; nevertheless, as all we know, this “magic” antigen has not still been described.
The phenomenon described in the case of erysipelas disease was also observed for tubercu-
losis (TB) patients. In 1929, Pearl published a large series of studies describing the inverse 
relationship between patients suffering from cancer and TB based on the evaluation of 
hundreds of autopsies [6]. Almost in parallel, 8 years before the publication of Pearl’s 
studies, the first girl was being administered with three doses of an attenuated strain of 
Mycobacterium bovis during the first week of her life. After the discovery of Mycobacterium 
tuberculosis as the causative agent of TB in humans by Koch, scientists raced to find a vac-
cine against this big killer. Nocard isolated the highly virulent species M. bovis, and in 1904, 
he transferred the strain to Albert Calmette and Camille Guérin who obtained the attenu-
ated strain by subculturing M. bovis over bile-potato medium every 3 weeks for 13 years. 
They demonstrated the avirulence without reversion in a guinea pig model, and the strain 
received the name of M. bovis Bacillus Calmette-Guérin (BCG) [7]. In 1932, the BCG was 
approved as safe vaccine against TB.
Therefore, studies on the use of BCG for cancer treatment started right after, and in 1935, 
Holmgren was the first scientist to report success in cancer patients [8]. As a continuation 
of the experiments he had begun in 1913 in which he evaluated the sensitivity to tuberculin 
in more than 600 gastric cancer patients, he intravenously injected repeated BCG doses 
in 28 cancer patients, most of them were gastric cancer patients [8]. In the 1950s, Rosental 
observed specifically lower incidence of leukemia in people who had received BCG at birth 
[9]. However, once the patient developed the tumor, there was no chance to previously 
immunize the patient, so the key point was to know whether the BCG had a curative role 
[10]. In the following years, many authors proved the efficacy of BCG in several cancer 
animal models including the bladder [11]. However, the spreading of the modern chemo-
therapy and radiotherapy for the treatment of cancer weakened the investigations on BCG 
as tumor treatment.
1.2. Post-chemotherapeutic era: consolidation studies
During the 1970–1980s, hundreds of articles were published in the field of immunotherapy 
using of BGC or BCG components for the treatment of cancer following different strategies. 
First, as was done until that moment, BCG was directly used intratumorally, and many stud-
ies in different cancers during these decades continued in this line of investigation. Following 
another strategy, some other scientists assayed the antitumoral effect of BCG as adjuvant in 
patients undergoing chemotherapy or radiotherapy for the treatment of lung [12], melanoma 
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[13], cervical [12], head and neck [12], or ovarian cancers [14], for instance. Another com-
pletely different strategy was the use of BCG as an adjuvant administering it together with 
tumor cell lysates [15]. In that period there were some authors who evaluated the antitumor 
efficacy of some mycobacterial fractions or other mycobacterium species in different cancer 
models, for instance, of hepatoma or sarcoma [16].
In 1974, Zbar and Rapp established the favorable conditions for obtaining a positive out-
come using a guinea pig model [17]. They determined the amount of bacilli that should be 
administered, that it was a mandatory a close contact between BCG and the tumor, and that 
BCG worked better against small tumors and immunocompetency of the host which permit 
to mount an immune response against the BCG [17]. Thanks to this postulates, in 1976, the 
urologist Morales and collaborators published the results of a successful small clinical trial in 
which they evaluated the intravesical administration of BCG in bladder cancer (BC) patients. 
It was not until 1990 that BCG was finally approved by the Food and Drug Administration 
(FDA) for the treatment of superficial BCG (Figure 1).
2. Mycobacteria as antitumor agents in the last 25 years
Although more than a century of research led finally only to the standard use of live BCG for 
BC treatment, the research trying to use mycobacteria components for cancer treatment has 
not been abandoned. In fact, in the last 25 years, several attempts for using different myco-
bacteria as immunotherapeutic agents for bladder cancer treatment have been carried out 
(Figure 1).
Despite the molecule or molecules of BCG responsible for its antitumor effect are still 
unknown, several genus-specific antigens have been described in mycobacteria cells, and 
most of them are known stimulators of the immune system. Specifically, the mycobacteria 
cell wall is rich in a variety of exclusive lipids, glycolipids, lipoproteins, glycans, and proteins 
that are recognized by immune receptors. Zlotta et al. [18] demonstrated that not only myco-
bacterial cell wall components are responsible for the antitumor effect but other fractions also 
triggered the production of Th1 cytokines and stimulated the cytotoxic activity against T24 
BC cells by peripheral blood cells. Antigens from different cell fractions are recognized by 
surface-located receptors present in antigen-presenting cells.
Molecules such as lipoarabinomannan (LAM), phosphatidylinositol mannosides, or heat-
shock proteins (HSP) are recognized by Toll-like receptors (TLR) 2 and 4 or mannose receptors; 
or antigens like trehalose mono- and dimycolate are agonist of C-type lectin receptors. Other 
mycobacteria antigens interact to specific intracellular immune receptors after being internal-
ized to the cell, such as unmethylated cytosine-guanosine nucleotide (CpG)-rich DNA motifs, 
muramyl dipeptide (MDP), or cytosolic DNA which bind to TLR-9, NOD2, or cyclic GMP-
AMP synthase (cGAS), respectively. After being processed inside the cells, some antigens are 
presented to T cells via CD1 receptors such as mycolic acids (MA) or trehalose and glucose 
mycolates. Signaling through these receptors can induce the production of cytokines and/or 
chemokines favoring a desirable pro-inflammatory profile in tumor microenvironment [19].
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Nevertheless, not all mycobacteria possess all the mentioned antigens, and even the structure 
of each antigen can vary between different species. Although some of these molecules such as 
LAM, trehalose dimycolate (TDM), or MA are present in all mycobacteria, the structure, for 
example, the presence or not of mannose residues in LAM structure, the length or the pres-
ence of unsaturations or oxygenated groups in the lipidic chains of TDM or MA, etc., deter-
mine the interaction to the corresponding immune receptor, and in consequence, the immune 
response is generated. The complexity of mycobacteria antigenicity is enormous leading even 
to the fact that different strains of the same species can have different antigenic pattern. The 
case of the antigenic profile of BCG is a good example. As it is known, from the seed strain 
originated in France by Albert Calmette and Camille Guérin, different strains were originated 
after subculturing the original BCG in different countries. Before being preserved by freezing, 
decades of subculturing originate deletions of some genome regions or even the duplication 
of some other genome regions. Today, we count about a decennium of different BCG strains 
[20] that are used broadly for BC treatment as well as for TB vaccination. Each different BCG 
strain possess or not some immunogenic antigens like phenolglycolipids, phthiocerol dimy-
cocerosates, and MBT64 protein antigen, or even they have two different MA profiles: some 
strains possess alpha, methoxy- and keto-MA, while some other possesses only alpha- and 
methoxy-MA. The relevance of these differences has tried to be related to BCG efficacy as 
antitumor agent or TB vaccine, but until nowadays the critical antigens are still not known.
In the following sections, the use of different mycobacteria or their components in the last 25 
years for urinary tract cancers will be reviewed. We will mainly focus on the use of these com-
ponents as unique antitumor agents, although the inclusion of studies in which mycobacterial 
antigens are used as adjuvants for tumor antigens or other therapies will also be mentioned.
3. Urinary tract cancers and mycobacteria
3.1. Bladder cancer and live BCG: a fruitful relationship
The immunotherapeutic ability of mycobacteria against cancer has the most successful exam-
ple in the case of the use of BCG for the treatment of high-risk non-muscle invasive bladder 
cancer (NMIBC) patients. All the conditions described by Zbar and Rapp are accomplished in 
intravesical BC treatment: a close cavity where mycobacteria can be loaded and being in close 
contact to tumor cells triggering also an immune response [17]. BC is one of the most com-
mon malignances in urology. The number of new cases and deaths of BC was 20.1 and 4.4 per 
100,000 men and women per year, being in 2013 estimated 587,426 people living with BC in 
the USA [21]. In 2016, 76,960 new cases of BC were estimated, and around 70% of them pres-
ent as NMIBC. Whether NMIBC patients are not treated after transurethral resection (TUR) 
of tumor, as much as 80% will experience disease recurrence and/or progression. Therefore, 
after TUR, the standard treatment for high-risk NMIBC patients consists in the intravesi-
cal instillation of live BCG. The bladder cavity allows a closed contact between the possible 
remaining tumor cells and the bacilli. For a short period of time (approximately 2 h), a high 
concentration of microorganisms (between 107 and 109 bacilli depending on the commercially 
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available preparations of BCG strains), besides being in contact to possible remaining tumor 
cells, initiates an immune cascade of events. Although the detailed chronogram and magni-
tude of these events are not totally understood, numerous studies have provided information 
about the immune cells and signals implicated in the action of BCG. Several excellent reviews 
have covered this field, explaining what is known until today, see [22, 23]. In summary, BCG 
firstly interacts with remaining bladder tumor cells inducing apoptosis and/or cell cycle arrest 
as demonstrated in in vitro experiments [24–26]. Moreover, internalization of the mycobacte-
ria triggers the production of cytokines and chemokines [27] that work as initial signals for 
the host immune system, leading to the infiltration of multiple immune cells into the blad-
der lumen, as observed in in vivo models of the disease [28, 29] as well as in BCG-treated 
patients [27]. Although the role of each infiltrated immune subsets—T cells, B cells, natural 
killer (NK) cells, macrophages, γδ cells, etc.—is still unknown, their presence is critical for an 
appropriate antitumor response [30]. This BCG-triggered immune response is finally able to 
fight against the presence of new tumors. BCG significantly reduces the risk of recurrence in 
treated patients, compared to NMIBC patients to whom only TUR is applied [31]. Moreover, 
in a recent meta-analysis of the literature, BCG has been confirmed as the only agent associ-
ated with decreased progression risk versus TUR alone [32].
Intravesical BCG therapy is then successful. In fact, the same protocol of instillations has been 
used in high-risk NMIBC patients for the last 30 years. But, although efficacious, BCG is not 
the perfect treatment. On the one hand, a percentage of patients do not respond to BCG for 
unknown reasons. On the other hand, a high percentage of patients suffer adverse events 
during the treatment.
3.2. Increasing efficacy
Several strategies are tried to solve the problem of unresponsive BCG patients. The main 
strategy consists of improving the immune response triggered by BCG, by combining BCG 
and immunomodulators or modifying genetically the bacterium for expressing these immu-
nomodulators. For instance, BCG plus an optimized interleukin (IL)-15 mutant significantly 
increased immune activation and reduced tumor burden and angiogenesis compared to the 
single agents in the carcinogen-induced rat NMIBC model [33]. The list of modified BCGs is 
long and comprises the expression of cytokines and chemokines—IL-2, interferon (IFN)-γ, 
GM-CSF, etc.—or immunodominant mycobacteria antigens like alpha-crystallin antigen 
(fibronectin-binding protein) complex (Ag85) [9, 22, 34]. These strategies seem to be promis-
ing for improving the efficacy of BCG alone as in vitro and in vivo experiments using animal 
models of the disease have shown. In that way, intravesical instillation of recombinant BCG 
strain expressing the fusion protein of IL-15 and Ag85B (BCG-IL-15) in tumor-bearing mice 
leads to a high neutrophil infiltration, increased presence of chemokines into the bladder, 
and prolonged survival rates compared to mice treated with BCG alone [35]. Recombinant 
BCG expressing human interferon-alpha 2b (hIFNα-2b) showed higher antiproliferative 
capacity on EJ BC cells after infection compared to wild-type BCG. Furthermore BCG-hIFNα-
2b-stimulated lymphocytes trigger the production of higher levels of IFN-γ, tumor necrosis 
factor (TNF)-α, and IL-12, together with higher cytotoxic activity against BC cells, compared 
to those treated with BCG [36].
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The study of the immune response triggered by BCG inside the bladder has revealed that 
an excess of IL-10 production in tumor microenvironment is detrimental for BCG efficacy. 
Another successful strategy is then the use of anti-IL-10 antibodies in combination to BCG for 
an improved effect. To block IL-10 receptor together with intravesical BCG reach high tumor 
regression rates in the murine orthotopic model of BC, enhancing also a systemic specific 
antitumor immune response compared to BCG alone [37].
Another strategy is the combination of BCG with TLR agonists. BCG together with TLR4 ago-
nist such as polyporus polysaccharide triggers the expression of activation molecules like CD80 
and CD40. In rat BC models, this combination therapy showed a synergic effect reducing inva-
siveness of cancer together with reduced adverse events originated by BCG alone [38]. Similarly 
BCG plus a TLR3 agonist (polyinosinic:polycytidylic, acid poly(I:C)) showed to be more effica-
cious on reducing MBT-2 bladder tumor growth in treated mice than the monotherapies [39].
Finally, it has been also demonstrated that the combination of live BCG together with chemo-
therapeutic treatments improves disease survival compared to BCG alone. Although some 
works showed no impact on the progression or survival rates of the patients [16, 17], recent 
study has demonstrated the beneficial effect of sequential intravesical treatment with BCG 
and mitomycin C. While in mice experiments an augmentation of beneficial M1 tumor-associ-
ated macrophages on tumor-bearing treated mice was observed, in treated patients increasing 
IL-2, IL-8, IL-10, and TNF-α urine levels during treatment and increased efficacy over BCG 
treatment alone were observed [40].
3.3. Reducing adverse events
The most critical adverse event regarding intravesical instillations of BCG is the possibility 
of the patient to be infected. Numerous cases of BCGosis have been described in the litera-
ture in the last 5 years [41, 42]. The main reason is a traumatic instillation that can lead to 
the dissemination of BCG throughout the systemic circulation. As soon as BCG showed to 
be an excellent option for BC treatment, researchers tried to compare its effect to non-viable 
mycobacteria, cell wall extracts, or even purified antigens from mycobacteria.
3.3.1. Purified mycobacteria antigens and non-viable mycobacteria
The majority of mycobacteria antigens, which are able to stimulate the immune system, 
have been widely studied in order to find epitopes for vaccines to prevent TB infection 
and also to develop immunodiagnostic tests for TB infection or disease. Researchers have 
taken advantage of the knowledge of these molecules for trying to use them as antitumor 
agents for BC. In this line of research, MPT-64 antigen, 38 kDa protein, Ag85 antigen, or 
mycobacterial DNA have been evaluated for their ability to treat BC. For MPT-64 a dose-
dependent response in survival rates was observed when instilled intravesically. The higher 
MPT-64 dose administrated provided higher survival rates in tumor-bearing treated mice 
than non-treated mice, triggering also a favorable IFN-γ systemic response [43]. When the 
38 kDa antigen was studied, a cytotoxic activity against T24 BC cells was observed in 38 
kDa antigen-activated peripheral blood mononuclear cells (PBMC), also in a dose-dependent 
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manner. Again, 38 kDa antigen-intravesically treated tumor-bearing mice survived longer 
than non-treated tumor-bearing mice [44], triggering a systemic response observed when 
splenocytes from treated mice respond specifically to the instilled antigen. Different works 
have evaluated the antitumor capacity of Ag85. Initially, the generation of cytolytic CD8 and 
an antitumor response was observed when cDNA from M. kansasii Ag85 antigen was trans-
ferred to MBT-2 BC cells and injected into mice [45]. Dendritic cells (DC) expressing Ag85 
have also shown to activate T cells triggering them to be cytotoxic to bladder tumors [46]. 
Ag85-dendritic cells induce the infiltration of T cells into tumor site triggering also the reduc-
tion of BC tumors in in vivo experiments [46]. Finally, mycobacterial DNA, specifically from 
BCG and from Mycobacterium phlei, has proven to have antitumor activity. DNA from BCG 
activates NK and triggers the production of IFN-α, IFN-β, and IFN-γ in splenocytes [47–49]. 
DNA from M. phlei is the responsible for the induction of cytokine release by monocytes and 
macrophages and to inhibit BC-cell proliferation by triggering apoptosis [50, 51].
Apart from purified antigens, complex extracts of mycobacteria have also been evaluated for 
BC treatment. The two principal assayed compositions have been a cell wall extract from BCG 
(composed by the cell wall skeleton or also called SPM-105) [52] and a mixture of cell wall 
plus DNA of M. phlei (MCNA) mentioned above. The main problem to work using cell wall 
preparations is the huge hydrophobic character of the mycobacteria cell wall. Thus, in both 
cases, although early in vitro studies showed promising results [51, 53], a reformulation of the 
cell wall extract was needed in order to optimize the solubility and stability of the preparation 
and facilitate the contact with target cells.
On the one hand, the BCG-cell wall skeleton (CWS) has been formulated into liposomes in 
which their surface was modified by an octaarginine (R8) anchor, an efficient cell-penetrat-
ing peptide [54–56]. Researchers demonstrated that R8-liposome-BCG-CWS binds to MBT-2 
murine BC cells inhibiting its growth in a syngeneic subcutaneous tumor model [57], being 
also efficacious in an intravesical BC rat model of the disease [58]. Furthermore, the formu-
lated extract is able to inhibit human BC growth in vitro [55], activated immune cells to a Th1 
profile, and leads to their cytotoxic activity against T24 and RT112 BC tumor cells [58].
On the other hand, M. phlei cell wall extract was initially formulated in mineral oil-in-water emul-
sion to be effective. After showing to induce BC apoptosis in vitro, the first clinical trial demon-
strated a similar rate of response in NMIBC patients who previously were refractory to BCG 
treatment and those without previous BCG treatment, indicating a possible role of M. phlei as a 
second-line drug after BCG failure [59]. From the initial composition evaluated, the formulation 
was improved by considering the inclusion of M. phlei DNA that, as previously explained, showed 
antitumor effect [50, 60]. The new composition, denominated MCNA, triggers both a direct effect 
by inducing apoptosis on cancer cells and an indirect effect by triggering an immune response 
[60]. MCNA was therefore evaluated in phase II and phase III clinical trials [61]. Both studies 
had some drawbacks: the number of patients finally considered was relatively small and, among 
them, a small percentage (around 2%) of patients showed serious adverse events, and around 
60–70% of patients in each study showed mild drug-related adverse events. In the phase III study, 
there was no signal of cancer in 25% of patients after 1 year and in 19% of patients after 2 years. 
Thus, MCNA could be a therapeutic option for patients in which the only therapeutic option is 
cystectomy after being refractory to BCG treatment, although further studies are needed [62].
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Finally, whole non-viable mycobacteria have also been evaluated for BC treatment. Contrary 
to purified antigens or cell extracts, the use of the whole bacteria warrants the presence of the 
whole antigenic profile, but depending on the inactivation method, some of the possible cru-
cial antigens can be altered or lost. On the one hand, heat-killing form has been the most stud-
ied although mycobacteria cells are damaged [63, 64], and on the other hand, γ-irradiation 
is the treatment which preserves better the integrity of the mycobacteria cell and maintains 
some metabolic activity [63].
Regarding in vitro BC cell growth inhibition, works using T24, J82, RT4, RT112, EJ28, or HT1376 
demonstrated that both heat-killed (HK) and γ-irradiated BCG, M. brumae, M. vaccae, or M. 
phlei, or HK MIP, inhibit BC proliferation similarly to live mycobacteria [63, 65–67], while other 
works found less growth inhibition of 253J and T24 cells significantly when HK BCG was used 
[68]. Unlike the observations made by the above mentioned authors, other authors found that 
HK BCG had no inhibitory effect in MGH BC cells [69]. Moreover, lower cytokine levels were 
produced by HK and γ-irradiated mycobacteria-infected cells than those infected by live bac-
teria [63, 69]. Between both treatments, γ-irradiated mycobacteria trigger cytokine levels closer 
to those induced by live mycobacteria, than those induced by HK mycobacteria. Regarding 
immune activation: induction of cytotoxicity by activated cells, induction of cytokine produc-
tion, and expression of activation markers on immune cells, again the immune response induced 
by live mycobacteria was higher than that triggered by non-viable mycobacteria [63, 66, 70, 71].
Using the orthotopic murine intravesical model of BC, HK BCG-treated mice survived simi-
larly to non-treated tumor-beating mice [72], together with lower production levels of Th1 
cytokines [72] that has also been related to inability to trigger T-cell infiltration into bladder 
cavity [28]. Interestingly, when live BCG or M. brumae was instilled in the first week of treat-
ment and subsequent instillations were done using γ-irradiated mycobacteria, significant pro-
longed survival rates were observed in tumor-bearing mice compared to untreated mice [71].
In BC patients, HK BCG instilled to previously live BCG nonresponders showed reduced toxicity 
and no increase in the risk of tumor recurrence [73]. Whole HK MIP has been instilled intravesi-
cally in five BC patients undergoing radiation therapy [74], maintaining 100% survival rates and 
recurrence-free rates. It has been also instilled in the treatment of BCG-refractory patients [75].
3.3.2. Live non-BCG mycobacteria
Concluding for the whole work compiled in the literature, it seems that live BCG provides the 
best option compared to the non-viable mycobacteria or mycobacteria fractions. Therefore, 
another feasible option as alternative to BCG for BC treatment is to consider the use of live 
non-pathogenic mycobacteria. However, few studies have considered them for BC treatment. 
As explained above, the majority of mycobacterium species is saprophytic and potentially 
share immunomodulatory antigens with BCG.
In a recent work of our research group [76], several non-pathogenic-considered mycobacteria 
(M. confluentis, M. chitae, M. chubuense, M. fallax, M. gastri, M. hiberniae, M. mageritense, M. 
obuense, M. phlei, and two strains of M. vaccae) were evaluated for their capacity to inhibit BC 
cell proliferation in vitro, compared to the effect of BCG Connaught. Among all the species 
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studied, M. brumae effect highlighted over the rest of results. Among the mycobacteria tested 
on 7 BC cell lines (T24, J82, RT112, SW780, HG-MG3, 5637, and RT4, belonging to different 
grades), M. brumae stood out for inhibiting BC-cell proliferation at a similar extent to BCG in 
high-grade cell lines and for showing an improved effect than BCG in low-grade cell lines. M. 
brumae triggered the expression of activation markers on macrophages at higher degree than 
M. phlei or M. vaccae did. Moreover, M. brumae was able to activate human PBMC ex vivo to 
kill BC cells by both direct contact and using only the soluble factors released by the activated 
PBMC. M. brumae also was able to activate a murine macrophage cell line [66, 76]. Using the 
murine orthotopic model of BC, a high percentage of live M. brumae-treated mice survived 
compared to BCG-treated and non-treated tumor-bearing mice, being the differences signifi-
cant only in comparison to non-treated-bearing mice [76, 77].
In vitro experiments have demonstrated that M. brumae cells did not persist alive inside both 
macrophages and BC cells after 72–96 h after infection [76, 77]. Besides in vivo experiments 
in the murine BC model showed that M. brumae do not persist neither in the spleen of mice 
treated intravesically with M. brumae, contrary to BCG, which is found in splenocytes after 
finishing the intravesical treatment [76, 77]. Nevertheless further security studies are needed 
to confirm the safety of this mycobacterium when it is used in its live form.
Apart from M. brumae, only M. vaccae, M. smegmatis, and M. kansasii have been studied in their 
live forms for BC treatment. According to our results [76], Baran and collaborators show that any 
of the three different strains of M. vaccae they studied was able to inhibit BC proliferation in vitro 
in a better way than BCG [78]. Regarding M. smegmatis, a recombinant strain expressing human 
TNF-α was studied. This strain inhibited EJ18, MGH-U1, RT4, and RT112 human BC-cell growth 
and triggered higher release of cytokines than the parental strain [79]. Later, inoculated in the 
heterotopic syngeneic mouse model, TNF-α-expressing M. smegmatis induced higher survival 
rates than the parental strain or BCG [80]. The authors also demonstrated a systemic immune 
response obtaining higher IFN-α levels in mycobacteria-stimulated spleen cultures from TNF-
α-M. smegmatis-treated mice. Finally, only one study showed that live M. kansasii triggers higher 
tumor reduction in the orthotopic murine BC model than a range of BC strains [81].
Although antitumor effect of mycobacteria is not considered for muscle-invasive BC, MIP 
plus radiation therapy in a small number of patients (5) showed disease-free survival more 
than 2 years [74].
3.4. Other renal and urinary tract cancers
Immunotherapy using mycobacteria components has been also applied in urinary tract can-
cers other than NMIBC.
For prostatic cancer, studies using BCG, M. phlei cell wall extract, MCC (a previous version 
of MCNA), SLR-172, and HSP65 have been carried out. Intravenous injection of BCG, but 
not subcutaneous injection, demonstrated to avoid metastasis of prostate adenocarcinoma 
(PA-III) cells in rats [82]. Intraperitoneal injection of BCG, however, avoids only propagation 
of PA-III cells in the peritoneal cavity. Thus, BCG and tumor cells have to be in the same com-
partment to prevent systemic propagation of the tumor [83]. Both live-attenuated BCG and 
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SRL172 plus autologous whole tumor cell vaccination were effective in the prevention of MAT-
LyLu tumors and increase survival rates in the rat model of prostate cancer. SRL172 alone did 
not provide any effect [84]. In this way, regular vaccination with tumor cells plus SRL172 in 
hormone-refractory prostate cancer patients demonstrated to be safe and induce cytokine 
production, specific antibody levels, and evidence of T-cell proliferation in response to the 
vaccinations [85]. Regular intradermal infection of only SRL172 in patients with advanced 
hormone-refractory prostate cancer demonstrated its safety and the ability to modulate cyto-
kine changes in these patients. Serum PSA diminished in 5 out of 10 patients, and an increase 
in IL-2 secreting PBMC was also shown [86]. Finally, MCC also showed an antitumor effect 
on prostatic cancer. In vitro, MCC induced both a dose-dependent proliferation reduction of 
LNCaP prostate cancer cells and the production of IL-12 and GM-CSF [87]. When adminis-
trated in the Dunning R3327-H adenocarcinoma of the prostate in rats, no effect was seen after 
intraperitoneal administration, but up to 50% of animals showed complete tumor regression 
after intratumor administration in small-volume tumors [88]. Finally, immunization with a 
recombinant GnRH vaccine conjugated to M. bovis HSP65 prolonged significantly survival, 
triggering suppression of local tumor growth, strong lymphocyte proliferative responses, and 
high IFN-γ levels in the orthotopic prostate cancer mouse model [89].
In renal cancer, SRL172 has been administrated in patients suffering from metastasis demon-
strating low toxicity and similar survival rates compared to patient treatment with cytokines 
(IL-2 or IFN-α) [82] and increased rates when synergized both treatments: SRL172 and antibod-
ies [90]. In stage IV renal cell cancer, patients treated with BCG plus irradiated autologous tumor 
cells, and later infused with autologous activated T cells, showed durable tumor responses [91].
Few studies have evaluated the efficacy of BCG in the treatment of upper tract urothelial cancer, 
but the conclusions driven from them indicate that there is no role for BCG in these cases [92, 93].
4. Future perspectives: a long history with room for improvement
The potential beneficial effect of mycobacteria as antitumor agents has been clearly demon-
strated after almost a century of observations and experimentation. But even in the case of 
BCG treatment for NMIBC patients, many issues remain under question: the appropriate 
schedule to reduce recurrence and progression without increasing adverse events [94–96]; the 
reason why a proportion of patients do not respond to BCG treatment; the detail description 
of immune mechanism which could permit to predict the response to the treatment; the possi-
bility of using other mycobacteria species that have shown similar or increased effective than 
BCG but with potential increased safety; etc. In fact, the experience using mycobacteria in 
BC is permitting novel approaches for improving its efficacy. In this sense, a critical point for 
mycobacteria efficacy is the delivery of mycobacteria or mycobacteria antigens into the tumor 
site. The optimization of mycobacteria formulation could be critical for reducing adverse-
associated events [97] and/or improving mycobacteria antitumor efficacy [77]. Moreover, the 
possibility to manipulate genetically mycobacteria for being vehicle for delivery antigens 
could lead also a chance to get more potent antitumor tools.
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